# Nxera to receive US$22.5 million in milestone payments from Neurocrine.

*biotech · news · 2026-04-12 · Wallstreet Online*

## Key points

- Neurocrine has initiated a Phase 2 clinical trial of NBI-1117570 in adults with schizophrenia.
- Nxera will receive US$22.5 million in milestone payments from Neurocrine, to be recognized in Q1 FY2026.
- NBI-1117570 is the second NxWave-discovered muscarinic agonist to advance to Phase 2 trials with Neurocrine.
- The Phase 2 trial will assess NBI-1117570's efficacy and safety in approximately 120 hospitalized schizophrenia patients.

**Companies:** Neurocrine Biosciences Inc., Nxera Pharma Co., Ltd.
**Countries:** Japan, United Kingdom, United States

[Read the full story on Wallstreet Online](https://www.wallstreet-online.de/nachricht/20721757-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia)

---

Canonical: https://newsio.io/n/85580875-1352-46ab-9ba7-2cbbeec6b499/nxera-to-receive-us22-5-million-in-milestone-payments-from-neurocrine-nbi-111757
Summarized by Newsio from Wallstreet Online. https://newsio.io/how-it-works